跳至主要内容
临床试验/NCT00051116
NCT00051116已完成2 期

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

Celgene Corporation1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2002年5月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
100
试验地点
1

研究概览

简要总结

To evaluate the response rate, response duration, and survival of patients treated with CC-5013 in a chronic dosing schedule versus a syncopated dosing schedule.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •History of histologically documented multiple myeloma with relapsed or resistant disease
  • •Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy documented within one week of registration. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
  • •Signed written informed consent and willingness to meet follow-up schedule and study procedure obligations

排除标准

  • 未提供

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验